Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients

Simple item page
dc.contributor.authorAl-Dasooqi, N.
dc.contributor.authorBowen, J.
dc.contributor.authorGibson, R.
dc.contributor.authorSullivan, T.
dc.contributor.authorLees, J.
dc.contributor.authorKeefe, D.
dc.date.issued2009
dc.descriptionThe original publication can be found at www.springerlink.com
dc.description.abstractPurpose: To characterise the gastrointestinal toxicities associated with Trastuzumab administration in HER2-overexpressing breast cancer patients. Methods: All patients (n = 46) who received Trastuzumab as a single agent or in conjunction with conventional anti-cancer treatment within the Royal Adelaide Hospital Cancer Centre from 2002–2007 were included in this study. A retrospective analysis of case-notes was conducted to investigate the toxicities associated with Trastuzumab. Results: Trastuzumab as a single agent induced toxicities following 22% of administrations. Gastrointestinal toxicities were observed following 12% of administrations and included nausea and vomiting, diarrhoea, abdominal pain and bloating. However, other prominent toxicities that were not related to the gastrointestinal tract were also observed including fatigue and lung symptoms (10.4%). Elderly patients (≥60 years) and those with metastatic disease experienced the highest frequency of toxicity. Conclusion: Trastuzumab induces a range of gastrointestinal toxicities in HER2-overexpressing breast cancer patients. These toxicities are separate to those caused by concurrent chemotherapy and/or radiotherapy.
dc.description.statementofresponsibilityNoor Al-Dasooqi, Joanne M. Bowen, Rachel J. Gibson, Thomas Sullivan, Jude Lees and Dorothy M. Keefe
dc.identifier.citationInvestigational New Drugs, 2009; 27(2):173-178
dc.identifier.doi10.1007/s10637-008-9152-1
dc.identifier.issn0167-6997
dc.identifier.issn1573-0646
dc.identifier.orcidBowen, J. [0000-0003-0876-0031]
dc.identifier.orcidGibson, R. [0000-0002-4796-1621]
dc.identifier.orcidSullivan, T. [0000-0002-6930-5406]
dc.identifier.orcidKeefe, D. [0000-0001-9377-431X]
dc.identifier.urihttp://hdl.handle.net/2440/53339
dc.language.isoen
dc.publisherKluwer Academic Publ
dc.source.urihttps://doi.org/10.1007/s10637-008-9152-1
dc.subjectHER2-overexpressing breast cancer
dc.subjectTargeted therapy
dc.subjectTrastuzumab
dc.subjectGastrointestinal tract
dc.subjectToxicity
dc.titleTrastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Anatomical Sciences publications